<DOC>
	<DOCNO>NCT03013998</DOCNO>
	<brief_summary>This screen multi-sub-study Phase 1b/2 trial establish method genomic screening follow assign accrue simultaneously multi-study `` Master Protocol ( BMAL-16-001-M1 ) . '' The specific subtype acute myeloid leukemia determine sub-study , within protocol , participant assign evaluate investigational therapy combination ultimate goal advance new target therapy approval . The study also include marker negative sub-study include screen patient eligible biomarker-driven sub-studies .</brief_summary>
	<brief_title>Study Biomarker-Based Treatment Acute Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<criteria>Adults , age 60 year old time diagnosis Subjects legal representative must able understand provide write informed consent Cohort Inclusion Criteria Group A : Subjects must previously untreated acute myeloid leukemia ( AML ) accord WHO classification prior treatment hydroxyurea . Prior therapy myelodysplastic syndrome ( MDS ) , myeloproliferative syndrome ( MPD ) , aplastic anemia permit hypomethylating agent . Cohort Inclusion Criteria Group B : Subjects must relapse refractory AML accord WHO classification . For study purpose , refractory AML define failure ever achieve CR recurrence AML within 6 month achieve CR ; relapse AML define others disease prior remission . ( Group B currently recruit . Expected begin recruit 3rd quarter 2017 . ) Isolated myeloid sarcoma ( meaning , patient must blood marrow involvement AML enter study ) Acute promyelocytic leukemia Symptomatic central nervous system ( CNS ) involvement AML Signs leukostasis require urgent therapy Disseminated intravascular coagulopathy active bleeding sign thrombosis Patients psychological , familial , social , geographic factor otherwise preclude give informed consent , follow protocol , potentially hamper compliance study treatment followup Any significant medical condition , include psychiatric illness laboratory abnormality , would preclude patient participate trial would confound interpretation result trial</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>